Ian Grady, Md Facs Speak On Mammaprint And It's Predictive To Chemotherapy Response

Ian Grady, MD FACS speak on MammaPrint And It's Predictive To Chemotherapy Response

Ian Grady, MD FACS Presents MammaPrint & BluePrint Case Study on 73-year-old ER+ BASAL Patient

MammaPrint Ultra Low Case Study By Dr. Ian Grady

Ian Grady, MD FACS Presents BluePrint Case Study on 60-year-old HER2 Patient

How MammaPrint and BluePrint Reclassifies Tumors Based on Tumor Biology, Ian Grady, MD FACS

Ian Grady, MD FACS Presents Case Study On 66-year-old Luminal A Patient

Ian Grady, MD FACS Presents Why We Test The Core Biopsy

Ian Grady, MD FACS Speaks On COVID-19 & Breast Care

Beth DuPree, MD FACS ABOHM Presents Case Study On Why MammaPrint & BluePrint Are Important

Jennifer Tittensor, MD FACS - Case Study - MammaPrint & BluePrint Preoperatively On Core Biopsy

Beth DuPree, MD FACS ABOHM Presents Information on MammaPrint & BluePrint Ordering On Core Bx

Jennifer Tittensor, MD FACS Presents Case Study On Why MammaPrint And BluePrint Is So Important

Jennifer Tittensor, MD FACS Presents The Benefits & Importance of MammaPrint

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence

NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype

Jennifer Tittensor, MD FACS Presents On Ordering MammaPrint & BluePrint on Clinically Low Risk Pts

Jennifer Tittensor, MD FACS Presents The Benefits Of BluePrint, Molecular Subtype Assay

Jennifer Tittensor, MD FACS Presents Case Study On MammaPrint Ultra Low 68-year-old Patient

Beth DuPree, MD FACS ABOHM Presents On MammaPrint & BluePrint And The Benefits of Genomic Testing